A STUDY BEFORE/AFTER THE IMPLEMENTATION OF AN ANTI-INFECTIOUS PRESCRIPTION AID
Sponsor
University Hospital, Montpellier (Other)
Overall Status
Completed
CT.gov ID
NCT05140213
Collaborator
(none)
371
1
8.6
43.3
Study Details
Study Description
Brief Summary
Anti-infective strategy is a major public health problem. This is a before-and-after study of an anti-infectious prescription tool with a comparison of mortality at 30 days (then 3 and 6 months) between the two inclusion phases of 6 months each.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
371 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
EVALUATION OF 30-DAY MORTALITY AFTER A VISIT TO THE LAPEYRONIE ADULT EMERGENCY DEPARTMENT OF THE CHU MONTPELLIER FOR SEPSIS OR SEPTIC SHOCK
Actual Study Start Date
:
Dec 12, 2020
Actual Primary Completion Date
:
Aug 12, 2021
Actual Study Completion Date
:
Aug 30, 2021
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Group 1 : Before "Before" phase including 186 patients patients included before the implementation of the prescription support tool |
Device: Anti-infectious prescription support tool
implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.
Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.
|
| Group 2 : After "After" phase including 185 patients patients included after the implementation of the prescription support tool |
Device: Anti-infectious prescription support tool
implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.
Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.
|
Outcome Measures
Primary Outcome Measures
- Numbers of patient 30-day mortality [30 day]
patient survival at 30 days
Other Outcome Measures
- Numbers of patient 90-day mortality [90 days]
patient survival at 90 days
- Numbers of patient 6 months mortality [6 months]
patient survival at 6 months
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
-
Major patients
-
Sepsis or septic shock
-
Oral consent
Exclusion criteria:
-
minor patients
-
death before antibiotherapy
-
care limitations
-
pre-hospital antibiotherapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Uh Montpellier | Montpellier | France | 34295 |
Sponsors and Collaborators
- University Hospital, Montpellier
Investigators
- Study Director: Hamza GHOMRANI, MD, University Hospital, Montpellier
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT05140213
Other Study ID Numbers:
- RECHMPL21_0685
First Posted:
Dec 1, 2021
Last Update Posted:
Dec 23, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms: